Effect of food intake on the pharmacokinetics of sarpogrelate and its active metabolite following oral administration to beagle dogs
暂无分享,去创建一个
[1] Guoqing Li,et al. Validated LC-MS/MS method for the determination of sarpogrelate in human plasma: application to a pharmacokinetic and bioequivalence study in Chinese volunteers. , 2010, Journal of pharmaceutical and biomedical analysis.
[2] R. Nirogi,et al. Liquid chromatography tandem mass spectrometry method for the quantification of sarpogrelate, a selective 5-HT(₂A) receptor antagonist, in plasma: application to a pre-clinical pharmacokinetic study. , 2010, Biomedical chromatography : BMC.
[3] Philimon N. Gona,et al. Pharmacological modeling and biostatistical analysis of a new drug , 2010 .
[4] T. Hanawa,et al. Development of sarpogrelate external preparation for intractable pain control. I. Pre-formulation study on application of modified beta-cyclodextrins. , 2010, Chemical & pharmaceutical bulletin.
[5] K. Kwon,et al. LC-MS/MS Assay Validation for a New Immune Modulator, JHL45, and its Major Metabolite in Plasma: Application to Pharmacokinetic Studies in Rats , 2009 .
[6] A. Terashi,et al. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial , 2008, Stroke.
[7] Kimberley A. Lentz,et al. Current Methods for Predicting Human Food Effect , 2008, The AAPS Journal.
[8] P. Marathe,et al. Development and validation of a preclinical food effect model. , 2007, Journal of pharmaceutical sciences.
[9] N. Dhalla,et al. Therapeutic potentials of sarpogrelate in cardiovascular disease. , 2006, Cardiovascular drug reviews.
[10] M. Rashid,et al. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. , 2004, Pharmacology & therapeutics.
[11] Philippe Manivet,et al. Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling. , 2003, Life sciences.
[12] H. Pertz,et al. In‐vitro Pharmacology of Sarpogrelate and the Enantiomers of its Major Metabolite: 5‐HT2A Receptor Specificity, Stereoselectivity and Modulation of Ritanserin‐induced Depression of 5‐HT Contractions in Rat Tail Artery , 1995, The Journal of pharmacy and pharmacology.
[13] Y. Tamao,et al. Antithrombotic Effect of MCI-9042, a New Antiplatelet Agent on Experimental Thrombosis Models , 1991, Thrombosis and Haemostasis.
[14] R. Kikumoto,et al. MCI–9042, a New Antiplatelet Agent Is a Selective S2-Serotonergic Receptor Antagonist , 1991, Thrombosis and Haemostasis.